Marksans Pharma Limited

₹ 433.8

ke advantage of these opportunities. " Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 433.8 cr +24.3 % (YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY)

24.3 %

e of these opportunities. " Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 433.8 cr +24.3 % (YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY) Q1FY23 PA

₹ 72.9

tunities. " Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 433.8 cr +24.3 % (YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY) Q1FY23 PAT ₹ 339.0 cr as

5.8%

Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O ₹ 433.8 cr +24.3 % (YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY) Q1FY23 PAT ₹ 339.0 cr as of June

₹ 60.2

R A N D C E O ₹ 433.8 cr +24.3 % (YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY) Q1FY23 PAT ₹ 339.0 cr as of June 30, 2022 Cash 5 Q1FY23 Highlights Topline

3.9%

E O ₹ 433.8 cr +24.3 % (YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY) Q1FY23 PAT ₹ 339.0 cr as of June 30, 2022 Cash 5 Q1FY23 Highlights Topline Profitab

₹ 339.0

(YoY) ₹ 72.9 cr -5.8% (YoY) Q1FY23 Revenue Q1FY23 EBITDA ₹ 60.2 cr -3.9% (YoY) Q1FY23 PAT ₹ 339.0 cr as of June 30, 2022 Cash 5 Q1FY23 Highlights Topline Profitability • Operating revenue was

₹433.8

r as of June 30, 2022 Cash 5 Q1FY23 Highlights Topline Profitability • Operating revenue was ₹433.8 cr. compared to ₹348.9 cr. in Q1FY22, an increase of +24.3% YoY driven by volume growth in existing

₹348.9

Cash 5 Q1FY23 Highlights Topline Profitability • Operating revenue was ₹433.8 cr. compared to ₹348.9 cr. in Q1FY22, an increase of +24.3% YoY driven by volume growth in existing products and new laun

24.3%

rofitability • Operating revenue was ₹433.8 cr. compared to ₹348.9 cr. in Q1FY22, an increase of +24.3% YoY driven by volume growth in existing products and new launches in the US and UK • Pricing ero

94%

e US continued in high single digits during the quarter, impacting the Generic Rx business • Over 94% of our revenues are from the regulated markets- USA , Europe, Australia & Canada • • • • Gro

₹218.9

es are from the regulated markets- USA , Europe, Australia & Canada • • • • Gross profit was ₹218.9 cr., increasing by +17.3% YoY. Gross margin was 50.5%, up 110bps QoQ but down 300bps YoY EBITDA wa

COMPETITORS

2

Store Brand OTC e-Commerce page

1

Rx COMPETITORS

1

Three phases of API manufacturing

1

Four step process of API integration

1

For more information please contact

1

Store Brand OTC e-Commerce page

Our products for the retailers are available in outlets and ecommerce as well With almost full range of Store brand OTC products available online today through the retailers 23 Why is Marksans retailers preferred partner for store brand OTC growth Quality expertise 2 1 Mass Customization Expertise 3 Low-cost manufacturing Regulatory Expertise 4 5 New Product Pipeline Consumer Marketing Expertise 6 24 Marksans edge over competition

Rx COMPETITORS

Lack of resources, infrastructure or experience to handle the requirements and complexity of store brands customization at a large scale STORE BRAND OTC

COMPETITORS

• • • • Do not have the critical scale to support Long Lasting Consumer Relationship Experience manufacturing brands in store Low-cost manufacturing in India • Quality systems • • Regulatory expertise ANDA investment NATIONAL BRAND OTC

COMPETITORS

Low profitability due to high marketing cost 25 2) Low-cost Manufacturing 26 Low-cost manufacturing base across key regions • Manufactures non-sterile liquids, ointments and powder sachets • Supplies to UK, West Africa & Middle East • Spread across 7,300 sq. meters C A PAC I T Y AC C R E D I TAT I O N S Farmingdale, USA 2 bn bottles per annum 1 bn tubes per annum 1 bn sachets per annum Goa, India • Manufactures hard gels, tablets and capsules • Spread over an area of 7000 sq. m • "Made in the USA” product offering • Added incremental packaging lines C A PAC I T Y ACC R E D I TAT I O N S 6 bn tablets and hard capsules per annum Southport, UK • Manufactures Capsules & Tablets • One of the biggest manufacturing facilities in Asia • Fully-automated unit spread over 18,000 sq. meters campus • Generic pharmaceuticals manufactured from this facility are exported across the globe AC C R E D I TAT I O N S C A PAC I T Y 2.4 bn softgel and hard gelatin capsules per annum 6 bn solid tablets per an

Four step process of API integration

• • • • Manufacturing Capacity Development of API Filing DMF Sponsor DMF into formulation Backward integration to lead to cost synergies Potential Gross & EBITDA margin expansion of ~500bps 32 Investing in new low-cost manufacturing capabilities ➢ Target – Adding new capacity of 8bn units per annum ➢ Products manufactured in new capacity - Oral solids, tablets, hard and softgels, ointments, gummies, creams ➢ Timeline - Within next 12-18 months Current Capacity (per annum) 8 bn 4 bn 6 bn 18 bn New Capacity (per annum) 8 bn 26 bn Location Goa UK USA Overall capacity across three locations Location New Overall capacity including the new location 33 Supplement growth through acquisitions Marksans Pharma has reinvented itself and witnessed growth momentum supported by organic and inorganic route. With a healthy cash position of ₹339 cr. (as of June 30, 2022) Strong Credit Rating Consistent cash generation ability Marksans will continue to supplement its growth profile: • • • • • Planning to

For more information please contact

Jitendra Sharma (CFO) Marksans Pharma Ltd Tel: +91 022 40012000 jitendra@marksanspharma.com Corporate Office 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2021 Marksans Pharma Limited, All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners. 77